Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Micro-Therapeutics launches new urological subsidiary:

This article was originally published in Clinica

Executive Summary

Micro-Therapeutics has formed a subsidiary to examine the possibilities for its Embolyx technology in urology and gynaecology. The new company, called Genyx Medical will be run by CEO Thomas Berryman, who is currently CFO of Micro-Therapeutics. Genyx will seek an initial round of financing. Micro-Therapeutics is backed by Guidant (see Clinica 784, p9). Embolyx is a biocompatible polymer dissolved in a solvent carrier, which rapidly precipitates as a solid in contact with body fluids. The new company plans to develop the product for urinary urge incontinence.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT086758

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel